1. Home
  2. ADV vs ANL Comparison

ADV vs ANL Comparison

Compare ADV & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Advantage Solutions Inc.

ADV

Advantage Solutions Inc.

N/A

Current Price

$32.89

Market Cap

523.2M

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$13.13

Market Cap

611.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ADV
ANL
Founded
1987
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
523.2M
611.1M
IPO Year
2019
2022

Fundamental Metrics

Financial Performance
Metric
ADV
ANL
Price
$32.89
$13.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$45.83
$20.00
AVG Volume (30 Days)
108.2K
197.8K
Earning Date
05-06-2026
04-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,542,642,000.00
N/A
Revenue This Year
$0.63
$36.02
Revenue Next Year
$0.45
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.49
$0.88
52 Week High
$47.45
$17.25

Technical Indicators

Market Signals
Indicator
ADV
ANL
Relative Strength Index (RSI) 45.19 57.09
Support Level $0.78 $12.41
Resistance Level $44.60 $13.29
Average True Range (ATR) 3.60 1.03
MACD -0.42 -0.05
Stochastic Oscillator 48.66 52.04

Price Performance

Historical Comparison
ADV
ANL

About ADV Advantage Solutions Inc.

Advantage Solutions Inc provides outsourced sales, marketing, merchandising, sampling, and retailer support services to consumer packaged goods manufacturers and retailers across North America. Its services are designed to support distribution, retail execution, shopper engagement, and private brand development across both physical and digital commerce environments. The company serves various clients across grocery, mass, club, retail pharmacy, convenience, and other channels. It operates through three reportable segments: Branded Services, Experiential Services, and Retailer Services. The majority of the revenue is derived from the Experiential Services segment, which provides in-store and digital sampling programs, demonstrations, and experiential events for manufacturers and retailers.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: